All Oncology News

An exploratory landmark analysis of the phase 3 ADAURA trial showed 8-year OS rates of 79% versuss 64% with placebo, with benefit maintained across stages and subgroups.

Frontline zidesamtinib produced a 94% response rate and 100% intracranial response rate in TKI-naive ROS1-positive advanced NSCLC.

First-line trastuzumab deruxtecan reduced the risk of progression or death by 37% compared with pembrolizumab plus chemotherapy in HER2-mutant non–small cell lung cancer.

Edgardo S. Santos Castillero, MD, discusses MAVERICK, B7-H3 ADC data, and tarlatamab sequencing in SCLC, plus molecular testing in a value-based practice.

Adding intercalated gefitinib to adjuvant chemotherapy improved DFS vs chemotherapy alone in completely resected stage II-IIIB EGFR-mutant NSCLC in a phase 3 trial.

The top 5 OncLive TV videos of the week cover insights in polycythemia vera, myelodysplastic syndrome, myelofibrosis, and acute myeloid leukemia.

A real-world study found just one-third of patients remained on adjuvant osimertinib at 3 years, with early discontinuation linked to worse disease-free survival.

Primary results from the phase 3 ARTEMIS-008 trial presented at WCLC 2026 showed risvutatug rezetecan reduced the risk of death by 54% and more than doubled PFS.

Tambotatug pelitecan improved survival and confirmed ORR in the phase 3 TAISHAN-302 trial presented at WCLC 2026.

Randomized dose-expansion data from the global phase 1 study establish the recommended phase 3 dose for the EGFR x HER3 bispecific ADC in the IZABRIGHT-Lung01 trial.

Final analysis of the phase 3 IMpower030 trial showed a median EFS of 62.8 months versus 34.9 months with placebo plus chemotherapy in stage IIB to IIIB disease.

First data from the phase 1B/2 BNT324-01 trial pair a PD-L1 and VEGF-A bispecific antibody with a B7H3-directed ADC in patients with SCLC.

Every-3-week and every-4-week tarlatamab regimens produced ORRs of 31% and 27% vs 40% with standard bi-weekly dosing in the phase 2 DeLLphi-309 trial.

The FDA approved sevabertinib in first-line HER2-mutant lung cancer, durvalumab plus tarlatamab boosted survival in ES-SCLC, and more.

The dose-finding DeLLphi-308 trial showed promising results for a more convenient administration of tarlatamab in patients with ES-SCLC.

The phase 3 LONESTAR trial was closed early for futility after added local consolidative therapy showed no OS or PFS benefit, including in oligometastatic disease.

Camizestrant plus palbociclib did not significantly improve progression-free survival vs anastrozole plus palbociclib in the first-line SERENA-4 trial.

Phase 1 data show that dibotatug produced a 60% overall response rate with a favorable safety profile in large granular lymphocytic leukemia.

The ASC4FIRST trial continued to show higher molecular response rates and better tolerability with asciminib than with standard TKIs in Ph-positive CML.

The FDA extended the review period for zanzalintinib plus atezolizumab in metastatic colorectal cancer.

Prophylactic tocilizumab before step-up dosing lowered CRS rates approximately 5-fold with teclistamab and talquetamab in relapsed/refractory myeloma.

Rusfertide preserved efficacy and safety benefits over placebo in both low- and high-risk polycythemia vera.

In the PIVOT-CLL trial, time-limited pirtobrutinib, venetoclax, and obinutuzumab produced deep, durable molecular remissions in treatment-naive CLL.

Roswell Park Comprehensive Cancer Center broke ground on an expansion of the Roswell Park Broadview Community Outreach and Engagement Center.

A prespecified analysis showed benefit with anselamimab in patients with kappa light chain AL amyloidosis.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

The selective BCR::ABL1 inhibitor ELVN-001 produced major molecular responses in previously treated chronic-phase CML, including after asciminib progression.

Actinomycin D plus low-dose cytarabine and venetoclax produced high remission rates in a retrospective cohort of patients with NPM1-mutated AML.

Revumenib added to intensive chemotherapy produced deep, MRD-negative remissions with a manageable safety profile in newly diagnosed AML.

Explore frontline CLL therapy choices: durable BTK inhibitors vs fixed venetoclax regimens, emerging combos, and what long-term safety data reveal.